leisure time -WSS

leisure time

author：focus 2025-09-07 17:24:17 - browse：28915

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Are embryos people? Reproductive medicine's future depends on the answer

Wikipedia

WSS

Obesity now affects over 1 billion people worldwide, study finds

Flu vaccine offering decent levels of protection this winter, new data show

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Why getting cancer drugs just got harder for rural patients

Virtual repurposing can help discover new uses for existing drugs

Readout Newsletter: Beam, Prozac, "TechBio" and more

leisure time

leisure time

leisure time

Virginia high school admissions case could be legal follow

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Medicare proposal to cover medical devices draws a mixed reaction

STAT Madness 2024: Meet the contenders

Guidelines to prevent youth baseball injuries need more muscle

International team creates first chimeric human

Apple is now the first public company to be valued at $3 trillion

Virtual repurposing can help discover new uses for existing drugs

At least 13 dead in Texas as scorching temps continue

Biotech companies concerned about China biosecurity crackdown

entertainment

Medicare Advantage isn’t working — for anyone

Kenai launches with $82 million for Parkinson’s stem cell therapy

Elisabeth Bik tackles the widespread issue of research misconduct

Pfizer highlights cancer drugs it thinks could reignite investor interest

Study fuels hope CAR

Change Healthcare cyberattack shows risk of industry consolidation

hotspot

explore

Wikipedia

focus